Clinical Trials
18 trialsNCT04299880 2023-11-08
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT00887536 2022-04-20
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
NSABP Foundation Inc
Phase 3 Completed
NCT01442649 2022-01-11
Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab
UNICANCER
Phase 2 Completed
NCT01442935 2021-06-18
Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases
UNICANCER
Phase 2 Completed
NCT04739202 2021-03-29
IMMUNOGAST
Hospices Civils de Lyon
Phase 2 Unknown
NCT02620800 2019-10-22
FABLOx
Celgene
Phase 1 Completed
NCT01206530 2019-04-18
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer
Abramson Cancer Center at Penn Medicine
Phase 1/2 Completed
NCT00847119 2017-08-29
xeberecto
Institut Català d'Oncologia
Phase 2 Completed
NCT01051934 2017-07-02
A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00548548 2017-06-14
AVAGAST
Genentech, Inc.
Phase 3 Completed
NCT00127036 2017-03-23
Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00719264 2017-03-20
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
Novartis
Phase 2 Completed
NCT00447330 2015-02-13
XAGastric
Duke University
Phase 2 Completed
NCT01554059 2014-11-10
New Beat
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Completed
NCT00600821 2013-11-08
A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.
Pfizer
Phase 2 Completed
NCT00597506 2012-12-27
BEV/EV
Duke University
Phase 2 Completed
NCT00226005 2012-05-09
PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer Research Team
Phase 2 Completed
NCT01175291 2011-12-05
FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Withdrawn